Burrill & Company Announces Investment in Sciona Inc.Burrill & Company Announces Investment in Sciona Inc.
November 8, 2004
Burrill & Company Announces Investment in Sciona Inc.SAN FRANCISCO--Burrill & Co. announced its investment in Sciona Inc., a company in the field of consumer-oriented genetic diagnostics currently located in Cambridge, England, but slated to relocate to New Haven, Conn., to be nearer to a strategic partner.Sciona has created a genetic diagnostic panel that enables manufacturers to customize personal care and nutrition products based on individual genetic makeup. "We are very impressed with Sciona's leadership position in the field of consumer-oriented genetic diagnostics," said G. Steven Burrill, chief executive officer of Burrill. Their CellF diagnostic panel represents the first large-scale entry into the field of nutragenomics. We are confident that with Sciona's research partnerships and their continued efforts to develop new diagnostics, they will remain in the lead of this exciting, new area of health and wellness. Burrill's Nutraceuticals Capital Fund, LP and their Life Sciences Capital Fund, LP, invested $1.7 million in a $6 million Series C Round. The round was co-led by Burrill and Prelude Ventures, of Cambridge, England. Other investors in the round included BASF Ventures, Semola Ltd., and DSM Ventures.
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023